HUTCHMED DRC
Price & Volume
Stats
See more52W Range | $11.50-$19.50 |
Market Cap | $2.6B |
Shares Short | 380,391 |
Financials
See moreRevenue (12 Mos) | $602.1M |
Revenue Growth (YoY) | -9.2% |
Gross Profit (12 Mos) | $53.7M |
Diluted EPS | $2.65 |
News
See moreYahoo Finance • 16 days ago
HUTCHMED Announces NDA Acceptance in China with Priority Review Status for Savolitinib for the treatment of Gastric Cancer Patients with MET Amplification
Yahoo Finance • 17 days ago
Hutchmed's NDA For Fanregratinib In Intrahepatic Cholangiocarcinoma Accepted In China
Yahoo Finance • 17 days ago
HUTCHMED Announces NDA Acceptance in China with Priority Review Status for Fanregratinib in Second-Line Intrahepatic Cholangiocarcinoma
Yahoo Finance • 29 days ago
HUTCHMED Initiates Global Clinical Development of ATTC Candidate HMPL-A251 in Patients with Solid Tumors
About
CEO | Mr. Chig Fung Cheng BEc, CA |
CFO | Mr. Chig Fung Cheng BEc, CA |
Address | Cheung Kong Center, Hong Kong, Hong Kong |
Sector | Healthcare |
Industry | Drug Manufacturers - Specialty & Generic |
Full-Time Employees | 1,780 |
